Hilltop Holdings Inc. Acquires 2,573 Shares of AbbVie Inc. $ABBV

Hilltop Holdings Inc. grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,279 shares of the company’s stock after buying an additional 2,573 shares during the quarter. AbbVie accounts for approximately 0.7% of Hilltop Holdings Inc.’s holdings, making the stock its 22nd biggest holding. Hilltop Holdings Inc.’s holdings in AbbVie were worth $13,031,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Texas Capital Bancshares Inc TX purchased a new stake in AbbVie during the third quarter valued at approximately $31,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at approximately $26,000. Caitlin John LLC purchased a new position in shares of AbbVie in the 3rd quarter worth approximately $33,000. Redmont Wealth Advisors LLC bought a new position in shares of AbbVie during the 3rd quarter valued at approximately $41,000. Finally, Financial Gravity Companies Inc. bought a new position in shares of AbbVie during the 2nd quarter valued at approximately $36,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $219.73 on Monday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm’s 50-day moving average is $224.33 and its 200 day moving average is $224.79. The company has a market capitalization of $388.51 billion, a PE ratio of 93.10, a P/E/G ratio of 0.76 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s payout ratio is presently 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase‑1 data for ABBV‑295 reported as encouraging — supports pipeline optionality beyond core brands and is constructive for long‑term revenue upside. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: AbbVie advanced a risankizumab dosing study, signaling continued investment in immunology — reinforces management’s growth strategy in a key therapeutic area. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: RBC Capital started coverage with an Outperform and $260 price target — a bullish institutional view that supports upside versus current levels. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Positive Sentiment: Consensus analyst stance remains supportive (“Moderate Buy”), which provides a baseline of buy‑side conviction. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Allergan Aesthetics‑affiliated providers earned top rankings in NY (beneficial for Allergan Aesthetics’ commercial reputation, but limited immediate impact on ABBV stock). New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Features and listicles (e.g., halal/debt‑free stock roundup, retirement income pieces) mention AbbVie but are peripheral to near‑term price movement. Is AbbVie Inc. (ABBV) One of the Debt Free Halal Stocks to Buy?
• Neutral Sentiment: Market reports forecasting growth in bipolar‑depression therapies expand the market opportunity for psychiatric drugs broadly; indirect for AbbVie unless tied to specific assets. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Shareholder governance concern: reports that the AbbVie CEO’s pay package has spiked above $30M can weigh on sentiment and prompt selling by governance‑focused funds. J&J, AbbVie CEOs See Pay Spike to More Than $30M
• Negative Sentiment: Analyst debate about immunology competition and valuation creates two‑sided risk—some analysts lift targets on growth, others flag competition that could cap upside, encouraging short‑term profit‑taking. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Morgan Stanley boosted their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $253.15.

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is owned by corporate insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.